NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totalling 385,600 shares, a decline of 18.1% from the August 31st total of 470,700 shares. Currently, 2.7% of the company’s shares are short sold. Based on an average trading volume of 392,400 shares, the short-interest ratio is presently 1.0 days.

NeuroSense Therapeutics Price Performance

Shares of NRSN traded up $0.01 during midday trading on Friday, hitting $1.28. The stock had a trading volume of 64,438 shares, compared to its average volume of 278,903. NeuroSense Therapeutics has a 1 year low of $0.40 and a 1 year high of $2.33. The stock’s 50 day moving average is $0.93 and its 200 day moving average is $1.16. The firm has a market cap of $17.49 million, a PE ratio of -1.51 and a beta of 1.52.

Institutional Trading of NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Armistice Capital LLC bought a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,584,000 shares of the company’s stock, valued at approximately $1,774,000. Armistice Capital LLC owned about 11.59% of NeuroSense Therapeutics as of its most recent filing with the Securities & Exchange Commission. 1.04% of the stock is owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.